Royalty Pharma plc
RPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $15,575,337 | $13,248,617 | $11,377,077 |
| - Cash | $938,944 | $631,908 | $1,087,720 | $929,026 |
| + Debt | $8,582,635 | $8,002,499 | $7,617,452 | $7,612,426 |
| Enterprise Value | – | $22,945,928 | $19,778,349 | $18,060,477 |
| Revenue | $609,291 | $578,665 | $568,247 | $593,641 |
| % Growth | 5.3% | 1.8% | -4.3% | – |
| Gross Profit | $609,291 | $578,665 | $568,247 | $593,641 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $525,052 | $159,303 | $498,694 | $400,112 |
| % Margin | 86.2% | 27.5% | 87.8% | 67.4% |
| Net Income | $288,217 | $30,176 | $238,349 | $208,214 |
| % Margin | 47.3% | 5.2% | 41.9% | 35.1% |
| EPS Diluted | 0.67 | 0.071 | 0.41 | 0.35 |
| % Growth | 845% | -82.7% | 17.1% | – |
| Operating Cash Flow | $639,627 | $426,972 | $596,076 | $742,525 |
| Capital Expenditures | $1,114 | $0 | $0 | $0 |
| Free Cash Flow | $640,741 | $426,972 | $596,076 | $742,525 |